| Over a month ago |
|
Hot Stocks
|
Precipio announces that… Precipio announces that as part of management's review of its current financing arrangements, it has terminated the equity line financing structure it had in place with Lincoln Park Capital. The equity line was used by Precipio to fund day-to-day operations and cover its operational cash burn that was required for the company's continued growth. With the company's current situation - growing revenues, improved gross margins, improving cash from gross profits - combined with our current cash position, management currently does not anticipate the need for additional capital raises of the type that Lincoln Park has provided us. "I'd like to thank our friends at Lincoln Park Capital for their help and support of the Company, particularly during the periods where this arrangement was critical to the Company's cash needs," said Ilan Danieli, Precipio's CEO. "We are now in a position where we have significantly extended our runway, and we anticipate that we will have the ability and the resources to rapidly grow the Company without further capital raises to fund ongoing operations in the next 24 months." ShowHide Related Items >><< - 06/08/21
- Precipio launches HemeScreen Anemia Panel
- 05/03/21
- Precipio launches COVID-19 rapid antibody test on Amazon's business platform
- 04/26/21
- Precipio expects $1M annualized reported revenues from HemeScreen POL by Q4
- 04/05/21
- Precipio enters ATM financing arrangement
- 04/01/21 Maxim
- Precipio price target raised to $7 from $2 at Maxim
- 03/30/21
- Precipio reports 2020 revenue $6.1M vs. $3.1M last year.
- 06/14/21
- Largest borrow rate increases among liquid names
- 05/26/21
- new option listings and three option delistings on May 26th
|
|
Options
|
Latest data shows the… Latest data shows the largest indicative borrow rate increases among liquid option names include: Arrival (ARVL) 270.81% +107.38, Upstart Holdings (UPST) 83.44% +6.61, Hertz Global Holdings (HTZGQ) 20.53% +4.64, Social Capital Hedosophia VI (IPOF) 5.59% +3.93, Aterian (ATER) 14.66% +2.58, Precipio (PRPO) 37.93% +1.72, Climate Change Crisis Real Impact I Acquisition Corp (CLII) 16.84% +1.05, SPI Energy (SPI) 27.28% +0.41, Lucira Health (LHDX) 49.49% +0.39, and Bionano Genomics (BNGO) 1.96% +0.31. ShowHide Related Items >><< - $125.55 /
-20.89 (-14.27%) - 05/14/21
- Third Point takes stakes in CoStar, Uber, exits Alibaba position
- 05/07/21
- Third Point discloses new long position in CoStar Group in investor letter
- 03/17/21
- Upstart to acquire Prodigy Software, terms not disclosed
- 02/16/21
- Third Point buys Upstart, exits Caesars in Q4
- 06/09/21
- SPI Energy subsidiary starts production on third-generation drivetrain products
- 04/12/21
- SPI Energy to acquire 6.5MW Solar PV, 5.45MWh energy storage project
- 03/15/21
- SPI Energy announces partnership with Common Energy
- 03/03/21
- SPI Energy subsidiary enters supply contract with NSW AHO
- 06/08/21
- Precipio launches HemeScreen Anemia Panel
- 05/03/21
- Precipio launches COVID-19 rapid antibody test on Amazon's business platform
- 04/26/21
- Precipio expects $1M annualized reported revenues from HemeScreen POL by Q4
- 04/05/21
- Precipio enters ATM financing arrangement
- 05/28/21
- Lucira Health names Kevin Collins as Chief Revenue Officer
- 05/28/21
- Lucira Health appoints Kevin Collins as CRO
- 05/12/21
- Lucira Health CHECK IT COVID-19 test kit now available on Amazon.com in U.S.
- 04/29/21
- Lucira Health's COVID-19 test kit to be manufactured by Jabil in new facility
IPOF Social Capital Hedosophia Holdings Corp. VI - 05/28/21
- Social Capital Hedosophia Holdings Corp. VI receives expected NYSE notice
- 06/10/21
- Hertz plan confirmed by court, says on target for June 30 Chapter 11 exit
- 05/12/21
- Hertz selects $6B bid From Knighthead, Certares, Apollo to fund Chapter 11 exit
- 05/05/21
- Hertz: Revised proposal from Knighthead, Certares, Apollo a 'superior proposal'
- 05/04/21
- Hertz receives revised reorganization proposal for Chapter 11 exit
CLII Climate Change Crisis Real Impact I - 04/28/21
- EVgo opens first three charging stations from collaboration with General Motors
- 04/28/21
- Blink, ChargePoint jump after GM announces charging network collaborations
- 04/28/21
- General Motors announces collaboration with seven 'major charging networks'
- 02/26/21
- EVgo says partnering to offer savings for EV drivers on Uber's platform
- 06/14/21
- Bionano Genomics names Richard Shippy as chief business officer
- 06/07/21
- Bionano Genomics appoints Jason Priar as CCO
- 06/07/21
- Bionano Genomics up over 8% in pre-market as top trending ticker on StockTwits
- 05/20/21
- Bionano Genomics granted patent for genomic coverage measurements
- 06/10/21
- Aterian announces pricing of $40M private placement
- 06/01/21
- Aterian announces certain stockholders agree to lock-up pacts
- 05/05/21
- Aterian issues statement on 'misleading' report by Culper Research
- 04/29/21
- Mohawk Group to rebrand as Aterian
- 05/13/21
- Arrival sees Q1 adjusted EBITDA loss EUR27M vs. EUR14M last year
- 04/21/21
- Arrival delivers first electric delivery van to UPS for testing
- 03/25/21
- Arrival begins trading on Nasdaq, first EVs expected in Q4
- 03/19/21
- CIIG Merger stockholders approve combination with Arrival
- 06/03/21 Barclays
- Arrival initiated with an Overweight at Barclays
- 04/05/21 Cowen
- Cowen starts Arrival at Outperform on 'unique microfactory approach'
- 04/05/21 Cowen
- Arrival initiated with an Outperform at Cowen
- $125.55 /
-20.89 (-14.27%) - 05/12/21 JMP Securities
- Upstart price target raised to $149 from $111 at JMP Securities
- 05/12/21 Piper Sandler
- Upstart price target raised to $152 from $143 at Piper Sandler
- 04/27/21
- Fly Intel: Top five analyst initiations
- 04/27/21 Piper Sandler
- Upstart initiated with an Overweight at Piper Sandler
IPOF Social Capital Hedosophia Holdings Corp. VI - 05/07/21 Alliance Global Partners
- Alliance Global says Aterian stock oversold, calls a top pick after recent drop
- 05/05/21 Roth Capital
- Aterian price target lowered to $30 from $40 at Roth Capital
- 04/01/21 Maxim
- Precipio price target raised to $7 from $2 at Maxim
CLII Climate Change Crisis Real Impact I - 05/04/21 William Blair
- William Blair downgrades Lucira Health on slowing Covid testing volumes
- 05/04/21 William Blair
- Lucira Health downgraded to Market Perform from Outperform at William Blair
- 04/13/21
- Fly Intel: Top five analyst downgrades
- 04/13/21 BofA
- Lucira Health downgraded to Underperform from Buy at BofA
- 02/08/21 Oppenheimer
- Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
- 01/26/21 Ladenburg
- Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
- 01/22/21 Maxim
- Bionano Genomics price target raised to $14 from $2 at Maxim
- 12/04/20 Roth Capital
- Bionano Genomics downgraded to Neutral from Buy at Roth Capital
- $125.55 /
-20.89 (-14.27%) - 05/11/21
- Upstart raises FY21 revenue view to roughly $600M from $500M
- 05/11/21
- Upstart sees Q2 revenue $150M-$160M, consensus $117.13M
- 05/11/21
- Upstart reports Q1 adjusted EPS 22c, consensus 15c
- 03/17/21
- Upstart sees FY21 revenue roughly $500M, consensus $354.3M
- 03/30/21
- Precipio reports 2020 revenue $6.1M vs. $3.1M last year.
- 05/13/21
- Lucira Health reports Q1 EPS (58c), consensus (33c)
- 04/13/21
- Lucira Health sees Q1 revenue $4.0M-$4.5M, consensus $9.42M
- 05/07/21
- Hertz reports Q1 adjusted EPS (33c) vs. ($1.78) a year ago
- 02/26/21
- Hertz reports Q4 adjusted EPS ($1.20), consensus (95c)
- 03/23/21
- Bionano Genomics reports Q1 revenue $3.9M, consensus $3.5M
- 03/23/21
- Bionano Genomics reports Q1 revenue $3.9M, consensus $3.5M
|
|
Hot Stocks
|
Precipio announced that… Precipio announced that it has launched the HemeScreen Anemia Panel as part of its suite of diagnostic tests. The purpose of this panel is to help physicians address one of the more significant clinical challenges they face: anemia of unknown cause. Precipio's HemeScreen Anemia Panel is a simple blood test that identifies molecular genetic errors which point to potentially fatal acute leukemia. Precipio's rapid, simple test, performed in the doctor's office, directs the physician to perform further appropriate hematology testing and treatment. ShowHide Related Items >><< - 05/03/21
- Precipio launches COVID-19 rapid antibody test on Amazon's business platform
- 04/26/21
- Precipio expects $1M annualized reported revenues from HemeScreen POL by Q4
- 04/05/21
- Precipio enters ATM financing arrangement
- 03/03/21
- Precipio appoints Richard Sandberg as chairman of the board
- 04/01/21 Maxim
- Precipio price target raised to $7 from $2 at Maxim
- 03/30/21
- Precipio reports 2020 revenue $6.1M vs. $3.1M last year.
- 05/26/21
- new option listings and three option delistings on May 26th
|
|
Options
|
New option listings for… New option listings for May 26th include Barclays ETN Plus Select MLP (ATMP), Aveanna Healthcare Holdings Inc (AVAH), iPath Pure Beta Broad Commodity (BCM), Biodesix Inc (BDSX), Brookfield Infrastructure Corporation (Class A Stock) (BIPC), Barclays ETN plus Shiller CAPE (CAPE), Centerra Gold Inc (CGAU), iPath US Treasury 5-year Bull (DFVL), iPath US Treasury 5-year Bear (DFVS), De spac ETF (DSPC), iPath Series B Bloomberg Natural Gas Subindex TR ETN (GAZ), Pacer iPath Gold ETN (GBUG), iPath Series B Carbon ETN (GRN), Barclays Bank Plc (GSP), iPath S&P (IMLP), iPath Series B Bloomberg Energy Subindex TR ETN (JJE), iPath Series B Bloomberg Softs Subindex TR ETN (JJS), iPath Bloomberg Lead Subindex Total Return ETN (LD), Maverix Metals Inc (MMX), iPath Pure Beta Crude Oil (OIL), Oatly Group AB (ADS) (OTLY), iPath Series B Bloomberg Platinum Subindex TR ETN (PGM), Precipio Inc (PRPO), AB Svensk Ekportkredit (RJZ), and Latham Group Inc (SWIM). Option delistings effective May 26th include Cubic Corp (CUB), FBL Financial Group Inc (Class A Stock) (FFG), and General Finance Corp (GFN). ShowHide Related Items >><< - 05/03/21
- Precipio launches COVID-19 rapid antibody test on Amazon's business platform
- 04/26/21
- Precipio expects $1M annualized reported revenues from HemeScreen POL by Q4
- 04/05/21
- Precipio enters ATM financing arrangement
- 03/03/21
- Precipio appoints Richard Sandberg as chairman of the board
- 02/16/21
- Maverix sees FY21 attributable gold equivalent ounces 27,000-30,000
- 02/16/21
- Maverix reports Q4 record gold equivalent ounces sold up 25% from last year
- 05/25/21
- United Rentals completes acquisition of General Finance Corp
- 05/24/21
- United Rentals completes tender offer for General Finance Corp
- 05/21/21
- FBL Financial shareholders approve transaction with FBPCIC
- 05/03/21
- FBL Financial rises 7.0%
- 04/23/21
- Capital Returns urges FBL Financial to negotiate higher price in FBPCIC deal
- 04/16/21
- Capital Returns: ISS recommends FBL Financial investors vote against merger
- 05/25/21
- Cubic trading halted, news dissemination
- 05/24/21
- Joint Corp. to replace Cubic in the S&P 600 at open on 5/27
- 05/19/21
- Cubic announces transit digital payment app for Google Pay
- 04/27/21
- Cubic receives shareholder approve of Veritas merger pact
- 05/18/21
- Centerra Gold announces Kyrgyzaltyn JSC prohibited from transferring shares
- 05/17/21
- Centerra Gold suspends 2021 guidance, three-year outlook for Kumtor Mine
- 05/17/21
- Centerra Gold calls Krgyz Parliament action 'clear violation' of rights
- 05/17/21
- Centerra Gold initates arbitration against Government of the Kyrgyz Republic
- 04/28/21
- Biodesix plans to launch 72-hour liquid biopsy test
- 04/26/21
- Biodesix to partner with GenScript on SARS-CoV-2 detection
- 04/11/21
- Biodesix releases new data at AACR on proteomic profiling
- 04/06/21
- Biodesix issued two patents from USPTO related to immunotherapy and testing
- 05/24/21 RBC Capital
- Aveanna initiated with an Outperform at RBC Capital
- 05/24/21 Jefferies
- Aveanna initiated with a Buy at Jefferies
- 05/24/21 Raymond James
- Aveanna initiated with a Strong Buy at Raymond James
- 05/24/21 JPMorgan
- Aveanna initiated with a Neutral at JPMorgan
BCM Canadian Imperial Bank of Commerce (CIBC) - 03/18/21 Morgan Stanley
- Biodesix price target raised to $25 from $20 at Morgan Stanley
- 03/17/21 Canaccord
- Biodesix a rare opportunity in precision oncology, says Canaccord
- 02/02/21 Canaccord
- Biodesix price target raised to $31 from $27 at Canaccord
- 01/11/21 Canaccord
- Biodesix price target raised to $27 from $26 at Canaccord
BIPC Brookfield Infrastructure - 01/06/21 Wells Fargo
- Wells Fargo says buy CenterPoint Energy, sell FirstEnergy
- 01/06/21 Wells Fargo
- Brookfield Infrastructure downgraded to Equal Weight from Overweight at Wells Fargo
- 11/23/20 Credit Suisse
- Brookfield Infrastructure Partners upgraded to Neutral at Credit Suisse
- 05/27/20 BofA
- Brookfield Infrastructure initiated with a Buy at BofA
- 05/20/21 National Bank
- Centerra Gold price target raised to C$11.25 from C$10.25 at National Bank
- 05/19/21 CIBC
- Centerra Gold price target lowered to C$9 from C$10 at CIBC
- 05/19/21 Raymond James
- Centerra Gold price target raised to C$10.50 from C$10.25 at Raymond James
- 05/19/21 Scotiabank
- Centerra Gold price target raised to C$10.50 from C$8 at Scotiabank
GRN General Re Corporation LD Louis Dreyfus Natural Gas - 05/20/21 National Bank
- Maverix Metals price target raised to C$8 from C$7.75 at National Bank
- 05/20/21 Canaccord
- Maverix Metals upgraded to Buy from Hold at Canaccord
- 04/23/21 National Bank
- Maverix Metals price target raised to C$7.75 from C$7.50 at National Bank
- 04/21/21 Canaccord
- Maverix Metals downgraded to Hold from Buy at Canaccord
- 04/01/21 Maxim
- Precipio price target raised to $7 from $2 at Maxim
- 05/18/21
- Fly Intel: Top five analyst initiations
- 05/18/21 KeyBanc
- KeyBanc bullish on Latham Group, initiates with an Overweight
- 05/18/21 Truist
- Truist starts 'secular growth story' Latham Group at Buy
- 05/18/21 Baird
- Latham Group to solidify fiberglass lead, Baird starts with Outperform
- 02/09/21
- Fly Intel: Top five analyst downgrades
- 02/09/21 Needham
- Cubic downgraded to Hold from Buy at Needham
- 02/09/21 Truist
- Cubic downgraded to Hold from Buy at Truist
- 02/09/21 Needham
- Cubic downgraded to Hold from Buy at Needham
- 05/04/21 Raymond James
- FBL Financial double downgraded to Underperform at Raymond James
- 05/04/21 Raymond James
- FBL Financial downgraded to Underperform from Outperform at Raymond James
- 09/04/20 Sidoti
- FBL Financial downgraded to Neutral from Buy at Sidoti
- 08/19/20
- Fly Intel: Top five analyst upgrades
- 05/06/21 DA Davidson
- General Finance Corp downgraded to Neutral from Buy at DA Davidson
- 05/06/21 DA Davidson
- General Finance Corp downgraded to Neutral from Buy at DA Davidson
- 03/30/21
- Precipio reports 2020 revenue $6.1M vs. $3.1M last year.
- 02/08/21
- General Finance Corp sees FY21 revenue $335M-$350M, two est. $319.93M
- 02/08/21
- General Finance Corp reports Q2 EPS 27c, two est. 12c
- 05/03/21
- FBL Financial reports Q1 adjusted EPS 96c, two estimates 82c
- 05/05/21
- Cubic reports Q2 adjusted EPS 15c, consensus 31c
- 02/08/21
- Cubic reports Q1 EPS 38c, consensus 0c
- 05/11/21
- Biodesix reports Q1 EPS (26c), consensus (17c)
- 03/16/21
- Biodesix reports Q4 EPS (25c), consensus (44c)
- 01/08/21
- Biodesix sees Q4 revenue $25M-$27M, consensus $15.55M
- 12/10/20
- Biodesix reports Q3 EPS ($31.93), consensus ($6.78)
|
| Over a quarter ago |
|
Hot Stocks
|
Precipio announced that… Precipio announced that currently, the contracted annualized revenues from signed customers for its HemeScreen POL testing system exceed $750,000 and for the reasons set forth below, by Q4-2021 this cohort is expected to result in reported quarterly revenues with an annualized run rate of $1,000,000. With an additional pipeline of over 30 prospective customers nationwide, Precipio currently reaffirms its forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021. The annualized reported revenues from the cohort of current signed customers are expected to increase to $1,000,000 by Q4-2021 because newly signed customers typically make smaller contractual commitments in order to evaluate their work flow and HemeScreen utility before committing to a larger number. In addition, during the coming months the HemeScreen offering is anticipated to broaden by the introduction of additional panels for other types of cancer. If successful, this expansion will improve patient care while providing meaningful financial benefits to customers' and to Precipio's bottom line. As Precipio continues to introduce additional assays to be utilized on the same platform, average revenue per customer will increase via incorporation and utilization of these assays within the POL's operations. ShowHide Related Items >><< - 04/05/21
- Precipio enters ATM financing arrangement
- 03/03/21
- Precipio appoints Richard Sandberg as chairman of the board
- 02/04/21
- Precipio launches online store for COVID-19 antibody tests, HemeScreen
- 01/28/21
- Precipio launches COVID-19 antibody testing at point-of-care
- 04/01/21 Maxim
- Precipio price target raised to $7 from $2 at Maxim
- 03/30/21
- Precipio reports 2020 revenue $6.1M vs. $3.1M last year.
|
|
Hot Stocks
|
Precipio announces a new… Precipio announces a new "At-The-Market" financing arrangement that improves its financing flexibility. As provided in the Company's prospectus supplement filed on April 2, 2021, Precipio will be able to sell shares from time to time through the ATM offering, up to an aggregate of $20M. The Company anticipates that this will be its primary financing method going forward. The ATM will be managed by Alliance Global Partners, an investment bank with which Precipio has been working since 2017. This arrangement will be used in an ongoing manner to finance Precipio's operations and provide the resources the Company needs to fuel its growth, particularly for its new HemeScreen offering for physician offices. As the Company continues to grow, having the most cost-effective, flexible financial tools at its disposal is critical to financing in the least dilutive manner. The ATM structure provides Precipio's management with more control over the timing, pricing, and proceeds it receives from selling shares into the market. ShowHide Related Items >><< - 03/03/21
- Precipio appoints Richard Sandberg as chairman of the board
- 02/04/21
- Precipio launches online store for COVID-19 antibody tests, HemeScreen
- 01/28/21
- Precipio launches COVID-19 antibody testing at point-of-care
- 01/20/21
- Precipio signs HemeScreen deals with two oncology groups
- 04/01/21 Maxim
- Precipio price target raised to $7 from $2 at Maxim
- 03/30/21
- Precipio reports 2020 revenue $6.1M vs. $3.1M last year.
|
|
Recommendations
|
Maxim analyst Jason… Maxim analyst Jason McCarthy raised the firm's price target on Precipio to $7 from $2 and keeps a Buy rating on the shares. The company's FY20 revenue grew in spite of the COVID headwinds, and while that growth was mainly attributed to the pathology services business, Precipio is shifting its core business toward the higher margin hematology diagnostic products and slowly away from sample selection and in-house testing, the analyst tells investors in a research note. ShowHide Related Items >><< - 03/03/21
- Precipio appoints Richard Sandberg as chairman of the board
- 02/04/21
- Precipio launches online store for COVID-19 antibody tests, HemeScreen
- 01/28/21
- Precipio launches COVID-19 antibody testing at point-of-care
- 01/20/21
- Precipio signs HemeScreen deals with two oncology groups
- 03/30/21
- Precipio reports 2020 revenue $6.1M vs. $3.1M last year.
|
|
Earnings
|
"The efforts of our… "The efforts of our team throughout the 2020 Covid shutdown were incredible, and the results speak for themselves", said Ilan Danieli, the Company's CEO. "We began to prepare in mid-March 2020 for the unknown; the individual efforts of our lab, R&D and sales personnel define the word "perseverance" and the phrase "commitment to excellence". We now have the opportunity to leverage a powerful growth engine which has been put through the challenges of 2020 and is ready for takeoff in 2021." ShowHide Related Items >><< - 03/03/21
- Precipio appoints Richard Sandberg as chairman of the board
- 02/04/21
- Precipio launches online store for COVID-19 antibody tests, HemeScreen
- 01/28/21
- Precipio launches COVID-19 antibody testing at point-of-care
- 01/20/21
- Precipio signs HemeScreen deals with two oncology groups
|